ArticleiScience2026
Factors linked to tigecycline-associated acute pancreatitis in a multicenter retrospective nested case-control study in patients.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline is associated with acute pancreatitis (TAAP), yet clinical factors linked to this adverse event require further identification. We conducted a multicenter, retrospective nested case-control study of 6942 patients receiving tigecycline. Cases were defined as patients who developed TAAP, while controls were matched in a 1:4 ratio by the same center and age. Among the cohort, 52 patients developed TAAP with an incidence of 0.75%. The median duration of tigecycline treatment was 7.5 days (IQR: 4-12.25 days), and the median time from the initiation of tigecycline to the onset of acute pancreatitis was 4 days (IQR: 1-8 days) in the case group. Multivariate analysis identified several factors associated with TAAP, including organ transplantation, elevated serum phosphorus, serum urea, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, serum gamma-glutamyl transferase (GGT), and concomitant use of esomeprazole; however, protopathic bias cannot be excluded. Our findings identified higher-risk individuals and support more cautious use during tigecycline therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.